Onco360 Achieves URAC Accreditation

Onco360, one of the nation’s largest independent providers of Oncology Pharmacy services, today announced that it has been awarded Specialty Pharmacy Accreditation from URAC, a Washington, DC-based accrediting organization that establishes quality standards for the health care industry. URAC’s Specialty Pharmacy Accreditation provides an external validation of excellence in Specialty Pharmacy Management and provides Continuous Quality Improvement (CQI) oriented processes that improve operations and enhance compliance.

“Onco360 is committed to providing the highest quality oncology pharmacy care to patients suffering from cancer, and we are proud to receive this accreditation,” said Paul Jardina, President and CEO of Onco360. “By applying for and receiving URAC accreditation, we demonstrated not only a commitment to our patients and their caregivers, but also to high quality and responsible healthcare.”

Accreditation is an evaluative, rigorous, transparent, and comprehensive process in which a health care organization undergoes an examination of its systems, processes, and performance by an impartial external organization (accrediting body) to ensure that it is conducting business in a manner that meets predetermined criteria and is consistent with national standards. “We believe this additional accreditation not only validates the excellence of our services, but also serves as an important guide for ongoing monitoring and improvement of our organization and processes,” continued Jardina.

Pharmacies located in the United States that dispense specialty drugs (those pharmaceuticals that usually require special handling, administration, unique inventory management, and a high level of patient monitoring and support) to consumers with specific chronic conditions, acute events, or complex therapies, and provide comprehensive patient education services and coordination with the patient and prescriber can apply for the URAC Specialty Pharmacy Accreditation program